Eltrombopag With or Without Hypomethylating Agent After Hypomethylating Agent Failure For Patients With Myelodysplastic Syndrome (MDS)

Status:
Completed

Trial end date:
2019-01-06

Target enrollment:

Participant gender:

The goal of this clinical research study is to learn if eltrombopag can help to control MDS. The safety of this drug will also be studied.

Phase 2

M.D. Anderson Cancer Center

GlaxoSmithKline
Novartis